InvivoGen's product citations
InvivoGen’s products are frequently cited in peer-reviewed publications for a wide variety of applications and uses. Browse our product citations below.
Please note: By clicking on the product name, you can access via the ‘Citations’ tab all references of the product (click ‘load more’).
Citations search
You can search by ‘Product Name’ or ‘Year’.
| Product | Citation | Year | Journal | Authors | Page |
|---|---|---|---|---|---|
| Jurkat Reporter Cells (NFAT) | Antibody-based redirection of universal Fabrack-CAR T cells selectively kill ... | 2022 | J Immunother Cancer | Kuo Y.C. et al. | DOI: 10.1136/jitc-2021-003752 |
| QUANTI-Luc™: Luciferase Detection Reagent | Antibody-based redirection of universal Fabrack-CAR T cells selectively kill ... | 2022 | J Immunother Cancer | Kuo Y.C. et al. | DOI: 10.1136/jitc-2021-003752 |
| LPS-EB (LPS from E. coli O111:B4) | Myeloid DNA methyltransferase3b deficiency aggravates pulmonary fibrosis by e... | 2022 | Respir Res. | Qin W. et al. | DOI: 10.1186/s12931-022-02088-5 |
| Puromycin | Cancer cells resist antibody-mediated destruction by neutrophils through acti... | 2022 | J Immunother Cancer | van Rees D.J. et al. | DOI: 10.1136/jitc-2022-004820 |
| IFN-α/β Reporter HEK 293 Cells | The Type I Interferon Pathway Is Upregulated in the Cutaneous Lesions and Blo... | 2022 | Front Med (Lausanne) | Rosa T.L.S.A. et al. | DOI: 10.3389/fmed.2022.899998 |
| QUANTI-Blue™ | The Type I Interferon Pathway Is Upregulated in the Cutaneous Lesions and Blo... | 2022 | Front Med (Lausanne) | Rosa T.L.S.A. et al. | DOI: 10.3389/fmed.2022.899998 |
| ODN 2216 - TLR9 ligand | The Type I Interferon Pathway Is Upregulated in the Cutaneous Lesions and Blo... | 2022 | Front Med (Lausanne) | Rosa T.L.S.A. et al. | DOI: 10.3389/fmed.2022.899998 |
| Poly(I:C) HMW | Toll-Like Receptor 3 Overexpression Induces Invasion of Prostate Cancer Cells... | 2022 | Am J Pathol. | Muresan X.M. et al. | DOI: 10.1016/j.ajpath.2022.05.009 |
| Bafilomycin A1 | Toll-Like Receptor 3 Overexpression Induces Invasion of Prostate Cancer Cells... | 2022 | Am J Pathol. | Muresan X.M. et al. | DOI: 10.1016/j.ajpath.2022.05.009 |
| Puromycin | Toll-Like Receptor 3 Overexpression Induces Invasion of Prostate Cancer Cells... | 2022 | Am J Pathol. | Muresan X.M. et al. | DOI: 10.1016/j.ajpath.2022.05.009 |
| TLR3-DN | Toll-Like Receptor 3 Overexpression Induces Invasion of Prostate Cancer Cells... | 2022 | Am J Pathol. | Muresan X.M. et al. | DOI: 10.1016/j.ajpath.2022.05.009 |
| HEK-Blue™ hDectin-1b Cells | Sulfavant A as the first synthetic TREM2 ligand discloses a homeostatic respo... | 2022 | Cell Mol Life Sci. | Gallo C. et al. | DOI: 10.1007/s00018-022-04297-z |
| HEK-Blue™ Detection | Sulfavant A as the first synthetic TREM2 ligand discloses a homeostatic respo... | 2022 | Cell Mol Life Sci. | Gallo C. et al. | DOI: 10.1007/s00018-022-04297-z |
| Pam2CSK4 | Sulfavant A as the first synthetic TREM2 ligand discloses a homeostatic respo... | 2022 | Cell Mol Life Sci. | Gallo C. et al. | DOI: 10.1007/s00018-022-04297-z |
| RAW-Blue™ Cells | Photothermal immunotherapy of melanoma using TLR-7 agonist laden tobacco mosa... | 2022 | Nanomedicine | Nkanga C.I. et al. | DOI: 10.1016/j.nano.2022.102573 |
| Puromycin | Glucocorticoids enhance chemotherapy-driven stress granule assembly and impai... | 2022 | J Cell Sci. | Schwed-Gross A. et al. | DOI: 10.1242/jcs.259629 |
| Normocin® - Antimicrobial Reagent | A novel β-catenin/BCL9 complex inhibitor blocks oncogenic Wnt signaling and d... | 2022 | Sci Adv. | Tanton H. et al. | DOI: 10.1126/sciadv.abm3108 |
| Primocin® | A novel β-catenin/BCL9 complex inhibitor blocks oncogenic Wnt signaling and d... | 2022 | Sci Adv. | Tanton H. et al. | DOI: 10.1126/sciadv.abm3108 |
| Poly(I:C) (HMW) VacciGrade™ | An intranasally administrated SARS-CoV-2 beta variant subunit booster vaccine... | 2022 | PNAS Nexus | Sui Y. et al. | DOI: 10.1093/pnasnexus/pgac091 |
| Puromycin | dCas9-mediated dysregulation of gene expression in human induced pluripotent ... | 2022 | Metab Eng. | Haellman V. et al. | DOI: 10.1016/j.ymben.2022.06.003 |